This relationship provides CancerGuide with exclusive commercial rights to a portfolio of well-published and rigorously-validated molecular signatures that predict response for targeted therapeutics as well as collaborative access to clinical research and new molecular discoveries from Duke, one of the nation’s premier cancer research institutions.
DURHAM, N.C.--(BUSINESS WIRE)--CancerGuide Diagnostics™, Inc. (CancerGuide™) today announced that it has entered into a research collaboration and licensing agreement with Duke University to discover and develop tests to support individualized cancer treatment decisions. This relationship provides CancerGuide with exclusive commercial rights to a portfolio of well-published and rigorously-validated molecular signatures that predict response for targeted therapeutics as well as collaborative access to clinical research and new molecular discoveries from Duke, one of the nation’s premier cancer research institutions.
“Duke Medicine is dedicated to ensuring that important new medical discoveries are brought into clinical practice”
CancerGuide will use these technologies with its pharmaceutical clients to improve the efficiency of the drug development process and to develop and commercialize novel clinical diagnostics through its existing agreement with LabCorp.
“Duke Medicine is dedicated to ensuring that important new medical discoveries are brought into clinical practice,” stated Robert L. Taber, PhD., Vice Chancellor of Corporate and Venture Development at Duke University. "We are very excited about the potential of our partnership with CancerGuide to bring about dramatic advances in the management of cancer treatment."
“CancerGuide has begun building a well-characterized genomic knowledge database compiled from years of clinical studies. This tool coupled with expert consultation by two of the foremost, pioneering scientists in the cancer genomic field, will give drug developers the highest level of actionable data and precision to enhance the likelihood of clinical success of their targeted therapeutic,” said Geoffrey Ginsburg, M.D., PhD., Director of the Center for Genomic Medicine in the Duke Institute for Genome Sciences and Policy.
“CancerGuide now has access to a suite of compelling technologies and know-how that has potential to guide therapy selection decisions for clinicians and to provide highly needed predictive tools for drug developers in the coming years,” stated Myla Lai-Goldman, M.D., CEO of CancerGuide.
About CancerGuide
CancerGuide Diagnostics, founded in 2006, is a life science company focused on development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients to make individualized treatment decisions. Additionally, CancerGuide offers unique and innovative methods for the development of clinical-grade companion diagnostic tests and tumor profiling services, to augment biomarker strategies of pharmaceutical and biotechnology companies. CancerGuide brings both commercial diagnostic expertise and renowned cancer genomic expertise together to benefit individualized cancer treatment decisions for practicing oncologists, pathologists, and pharmaceutical researchers and developers. The company is financially backed by a $10.5 million private equity financing agreement led by Intersouth Partners, Hatteras Venture Partners and LabCorp. In 2010, CancerGuide also completed a strategic license and commercialization agreement with Laboratory Corporation of America Holdings (LabCorp). Under the agreement, LabCorp and CancerGuide will collaborate in the development and commercialization of CancerGuide’s molecular oncology assays. The agreement also gives LabCorp’s global Clinical Trials Services Division, Esoterix, exclusive commercial rights to use CancerGuide’s assays in connection with clinical trial pharmaceutical support services. CancerGuide’s strategic partnership model is laying the foundation for an unprecedented “speed-to-market” for personalized oncology diagnostic discoveries, and the company welcomes inquiries from entities with well-validated, compelling molecular technology seeking commercialization expertise.
Further information about CancerGuide can be found at www.cancerguidedx.com or by calling 919.474.CGDX (2439).
Note: CancerGuide™, CancerGuide Diagnostics™, and related marks are pending registered trademarks of CancerGuide Diagnostics, Inc.
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to or implying forthcoming clinical products and the status of regulation by the U.S. Food and Drug Administration (FDA) of our test service. These forward-looking statements speak only as of the date hereof. CancerGuide disclaims any obligation to update these forward-looking statements.
